The role of dysregulated glucagon secretion in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 13, Issue SUPPL. 1, 2011, Pages 126-132

  D'alessio, D ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Glucagon; Glucagon like peptide 1; Hepatic glucose production; Type 2 diabetes; cell

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

DIABETIC PATIENT; GENETIC POLYMORPHISM; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; REVIEW; SIGNAL TRANSDUCTION;

EID: 79961187183     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01449.x     Document Type: Review

References (68)

1. Muller WA, Faloona GR, Unger RH. Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med 1973; 54: 52-57.
2. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28: 253-283.
3. Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007; 28: 84-116.
4. Dobbins RL, Davis SN, Neal DW, Cobelli C, Jaspan J, Cherrington AD. Compartmental modeling of glucagon kinetics in the conscious dog. Metabolism 1995; 44: 452-459.
5. Felig P, Wahren J, Hendler R. Influence of physiologic hyperglucagonemia on basal and insulin-inhibited splanchnic glucose output in normal man. J Clin Invest 1976; 58: 761-765.
6. Del Prato S, Castellino P, Simonson DC, DeFronzo RA. Hyperglucagonemia and insulin-mediated glucose metabolism. J Clin Invest 1987; 79: 547-556.
7. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987; 36: 274-283.
8. Raju B, Cryer PE. Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol Endocrinol Metab 2005; 289: E181-E186.
9. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970; 49: 837-848.
10. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 106-110.
11. Unger RH, Eisentraut AM, McCall CM, Madison LL. Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. J Clin Invest 1962; 41: 682-689.
12. Aronoff SL, Bennett PH, Unger RH. Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. J Clin Endocrinol Metab 1977; 44: 968-972.
13. Unger RH. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 1985; 28: 574-578.
14. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973; 182: 171-173.
15. Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes 2010; 59: 2697-2707.
16. Liljenquist JE, Mueller GL, Cherrington AD et al. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 1977; 59: 369-374.
17. Matsuda M, Defronzo RA, Glass L et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 2002; 51: 1111-1119.
18. Nielsen MF, Wise S, Dinneen SF, Schwenk WF, Basu A, Rizza RA. Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis. Diabetes 1997; 46: 2007-2016.
19. Lins PE, Wajngot A, Adamson U, Vranic M, Efendic S. Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia. Diabetes 1983; 32: 633-636.
20. Unger RH. Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 1978; 27: 1691-1709.
21. Deng S, Vatamaniuk M, Huang X et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004; 53: 624-632.
22. Ward WK, Bolgiano DC, Mcknight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 74: 1318-1328.
23. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 1984; 74: 2296-2299.
24. Greenbaum CJ, Havel PJ, Taborsky GJ Jr, Klaff LJ. Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. J Clin Invest 1991; 88: 767-773.
25. Raskin P, Aydin I, Yamamoto T, Unger RH. Abnormal alpha cell function in human diabetes: the response to oral protein. Am J Med 1978; 64: 988-997.
26. Raskin P, Aydin I, Unger RH. Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. Diabetes 1976; 25: 227-229.
27. Taylor R, Magnusson I, Rothman DL et al. Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest 1996; 97: 126-132.
28. Gosmanov NR, Szoke E, Israelian Z et al. Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care 2005; 28: 1124-1131.
29. Israelian Z, Gosmanov NR, Szoke E et al. Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes. Diabetes Care 2005; 28: 2691-2696.
30. Raju B, Cryer PE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes 2005; 54: 757-764.
31. Ahren B, Larsson H. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 2001; 44: 1998-2003.
32. Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 2000; 23: 650-657.
33. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-29.
34. Elder DA, Prigeon RL, Wadwa RP, Dolan LM, D'alessio DA. Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J Clin Endocrinol Metab 2006; 91: 185-191.
35. Tfayli H, Bacha F, Gungor N, Arslanian S. Islet cell antibody-positive versus -negative phenotypic type 2 diabetes in youth: does the oral glucose tolerance test distinguish between the two? Diabetes Care 2010; 33: 632-638.
36. Tschritter O, Stumvoll M, Machicao F et al. The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes 2002; 51: 2854-2860.
37. Schwanstecher C, Meyer U, Schwanstecher M. KIR 6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic beta-cell ATP-sensitive K(+) channels. Diabetes 2002; 51: 875-879.
38. Brand CL, Jorgensen PN, Knigge U et al. Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am J Physiol 1995; 269: E469-E477.
39. Gelling RW, Du XQ, Dichmann DS et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 2003; 100: 1438-1443.
40. Gerich JE, Lorenzi M, Bier DM et al. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med 1975; 292: 985-989.
41. Ward WK, Best JD, Halter JB, Porte D Jr. Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man. J Clin Endocrinol Metab 1984; 58: 449-453.
42. Holste LC, Connolly CC, Moore MC, Neal DW, Cherrington AD. Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol 1997; 273: E488-E496.
43. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 1999; 277: E283-E290.
44. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053-4059.
45. Parker JC, Andrews KM, Allen MR, Stock JL, Mcneish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 2002; 290: 839-843.
46. Conarello SL, Jiang G, Mu J et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 2007; 50: 142-150.
47. Hancock AS, Du A, Liu J, Miller M, May CL. Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Mol Endocrinol 2010; 24: 1605-1614.
48. Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 2009; 296: E415-E421.
49. Sloop KW, Cao JX, Siesky AM et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004; 113: 1571-1581.
50. Longuet C, Sinclair EM, Maida A et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 2008; 8: 359-371.
51. Sinclair EM, Yusta B, Streutker C et al. Glucagon receptor signaling is essential for control of murine hepatocyte survival. Gastroenterology 2008; 135: 2096-2106.
52. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001; 44: 2018-2024.
53. Parker JC, McPherson RK, Andrews KM et al. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes 2000; 49: 2079-2086.
54. Pfeifer MA, Halter JB, Judzewitsch RG et al. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man. Diabetes Care 1984; 7(Suppl 1): 25-34.
55. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
56. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
57. Gromada J, Rorsman P. New insights into the regulation of glucagon secretion by glucagon-like peptide-1. Horm Metab Res 2004; 36: 822-829.
58. D'alessio DA, Vogel R, Prigeon R et al. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 1996; 97: 133-138.
59. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M. Exendin(9-39) amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998; 101: 1421-1430.
60. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010; 59: 1765-1770.
61. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996; 19: 580-586.
62. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
63. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
64. Dupre J, Behme MT, Mcdonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004; 89: 3469-3473.
65. Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 2006; 38: 838-844.
66. Chang AM, Jakobsen G, Sturis J et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003; 52: 1786-1791.
67. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
68. Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92: 1249-1255.